Corporate
Jan. 2, 2009
Top Deals
Lawyers from Latham & Watkins can breathe easier after finishing a deal worth up to $900 million between London-based pharma giant AstraZeneca Plc and their client, MAP Pharmaceuticals Inc. - a biopharmaceutical company that produces asthma medication - to develop and commercialize the company's pediatric asthma drug.
Latham Advises On Biopharma Deal
Lawyers from Latham & Watkins can breathe easier after finishing a deal worth up to $900 million between London-based pharma giant AstraZeneca Plc and their client, MAP Pharmaceuticals Inc. - a biopharmaceutical company that produces asthma medication - to develop and commercialize the company's pediatric asthma drug.
The deal, announced Dec. 19, is subject to regulatory approval under the Hart-Scott-Rodino Act....
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In